Bellevue Group AG Lowers Holdings in ESSA Pharma Inc. (NASDAQ:EPIX)

Bellevue Group AG lowered its position in shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) by 0.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,889,583 shares of the company’s stock after selling 9,000 shares during the quarter. ESSA Pharma accounts for 1.0% of Bellevue Group AG’s investment portfolio, making the stock its 26th largest holding. Bellevue Group AG owned 17.83% of ESSA Pharma worth $66,983,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. EntryPoint Capital LLC acquired a new stake in ESSA Pharma in the first quarter valued at about $38,000. BNP Paribas Financial Markets raised its stake in shares of ESSA Pharma by 164.9% during the 4th quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock worth $379,000 after buying an additional 35,771 shares in the last quarter. Finally, RTW Investments LP acquired a new stake in shares of ESSA Pharma in the 4th quarter valued at approximately $15,171,000. Institutional investors and hedge funds own 75.12% of the company’s stock.

ESSA Pharma Stock Down 1.5 %

Shares of NASDAQ EPIX traded down $0.08 during midday trading on Friday, hitting $5.34. The company had a trading volume of 28,885 shares, compared to its average volume of 27,278. The firm has a market capitalization of $236.90 million, a price-to-earnings ratio of -8.48 and a beta of 1.83. ESSA Pharma Inc. has a twelve month low of $2.58 and a twelve month high of $11.67. The business has a 50-day simple moving average of $5.45 and a two-hundred day simple moving average of $7.25.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). On average, equities analysts forecast that ESSA Pharma Inc. will post -0.83 EPS for the current year.

Analysts Set New Price Targets

Separately, Oppenheimer reiterated an “outperform” rating and issued a $17.00 price objective on shares of ESSA Pharma in a research report on Thursday, May 16th.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.